CIK 0001061983 · Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 943291317
- Phone
- (650) 624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,208,275
- in 16 filings, $12.2M under 10b5-1 plans
Net −$12,208,275. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-02 | HENDERSON JOHN T Director | Option exercise 10b5-1 | +8,750 | $10.00 | $88K | 83,328 |
| 2025-12-02 | HENDERSON JOHN T Director | Sale 10b5-1 | −8,750 | $63.90 | $559K | 74,578 |
| 2025-12-02 | HENDERSON JOHN T Director | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −8,750 | 0 | ||
| 2025-12-02 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +2,200 | $10.60 | $23K | 142,810 |
| 2025-12-02 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,200 | $63.89 | $141K | 140,610 |
| 2025-12-02 | Malik Fady Ibraham EVP Research & Development | Option exercise · Incentive Stock Option (Right to Buy) 10b5-1 | −2,200 | 2,200 | ||
| 2025-12-01 | Kaye Edward M. MD Director | Option exercise 10b5-1 | +8,064 | $12.40 | $100K | 18,041 |
| 2025-12-01 | Kaye Edward M. MD Director | Option exercise 10b5-1 | +20,000 | $14.25 | $285K | 38,041 |
| 2025-12-01 | Kaye Edward M. MD Director | Sale 10b5-1 | −28,064 | $66.72 | $1.9M | 9,977 |
| 2025-12-01 | Kaye Edward M. MD Director | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −8,064 | 0 | ||
| 2025-12-01 | Kaye Edward M. MD Director | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −20,000 | 0 | ||
| 2025-12-01 | Harrington Robert Arthur Director | Sale 10b5-1 | −2,150 | $66.80 | $144K | 18,542 |
| 2025-11-19 | PARSHALL B LYNNE Director | Sale 10b5-1 | −5,000 | $64.73 | $324K | 22,933 |
| 2025-11-18 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +2,200 | $10.60 | $23K | 142,810 |
| 2025-11-18 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,200 | $66.45 | $146K | 140,610 |
| 2025-11-18 | Malik Fady Ibraham EVP Research & Development | Option exercise · Incentive Stock Option (Right to Buy) 10b5-1 | −2,200 | 4,400 | ||
| 2025-11-14 | Hessekiel Jeffrey Chief Legal & Admin Officer | Grant or award | +87,297 | 87,297 | ||
| 2025-11-11 | Kaye Edward M. MD Director | Option exercise 10b5-1 | +5,175 | $9.66 | $50K | 15,152 |
| 2025-11-11 | Kaye Edward M. MD Director | Sale 10b5-1 | −5,175 | $65.08 | $337K | 9,977 |
| 2025-11-11 | Kaye Edward M. MD Director | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,175 | 0 |
Page 15 of 22 · 429 trades